Belgian Media Stock News

Barco (ENXTBR:BAR) has released its full year 2025 results, reporting sales of €963.84 million and net income of €71.56 million. These figures help frame the recent share performance. See our latest analysis for Barco. Despite the solid full year 2025 figures, Barco’s share price has softened, with a 30 day share price return of an 11.79% decline and a 1 year total shareholder return of a 4.9% loss, suggesting momentum has been fading recently. If these results have you thinking about where...

If you are trying to work out whether Solvay shares at €27.84 are starting to look attractively priced, you are in the right place. The stock has returned 4.0% over the last 7 days and 2.7% over the past month, while the 1 year return sits at a 9.2% decline, compared with longer term returns of 44.3% over 3 years and 73.9% over 5 years. These moves come against a backdrop where investors have been reassessing Solvay's positioning in the materials sector and its portfolio after previous...

If you are wondering whether SCR-Sibelco is priced fairly today, you are not alone. The stock often attracts attention from investors trying to work out if they might be overpaying or missing an opportunity. Over the short term, the share price has been mixed, with a 1.3% return over the last 7 days, a 0.8% decline over 30 days, and returns of 12.7% decline year to date and 5.7% decline over the past year, extending to a 10.9% decline over five years. Recent news coverage has mainly focused...

Key Insights Significant control over Biotalys by private equity firms implies that the general public has more power...

As European markets experience volatility amid global concerns about AI disruption, the pan-European STOXX Europe 600 Index has managed to reach new highs, reflecting a cautiously optimistic sentiment. In this dynamic environment, identifying promising stocks requires a keen understanding of market trends and economic indicators that can reveal potential growth opportunities.

As European markets experience volatility amid global concerns over AI disruption, the pan-European STOXX Europe 600 Index managed to hit a new high, ending the week with a slight gain. In such an environment, dividend stocks can offer investors a degree of stability and income potential, making them attractive options for those looking to navigate uncertain market conditions.

Montea Comm. VA overview Montea Comm. VA (ENXTBR:MONT) is back in focus after investors reacted to its recent share performance, with the stock showing mixed returns over the past week, month and past 3 months. The logistics focused real estate group, active across Belgium, the Netherlands, France and Germany, now trades around €74. This has prompted fresh interest in how its long term total returns compare with its current valuation profile. See our latest analysis for Montea Comm...

Aedifica/SA (ENXTBR:AED) has wrapped up FY 2025 with fourth quarter revenue of €90.5 million and basic EPS of €1.06. Trailing 12 month figures show revenue of €369.6 million and EPS of €5.14. The company has reported revenue increasing from €346.5 million to €369.6 million on a trailing 12 month basis, with EPS rising from €4.31 to €5.14 over the same period. Quarterly revenue ranged between €90.2 million and €95.4 million, and EPS between €0.71 and €1.70 across the last six reported...

It's been a good week for Anheuser-Busch InBev SA/NV ( EBR:ABI ) shareholders, because the company has just released...

Shareholders might have noticed that KBC Group NV ( EBR:KBC ) filed its yearly result this time last week. The early...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Competitive pressure in generalized myasthenia gravis The European Commission’s approval of Amgen’s Uplizna for generalized myasthenia gravis puts fresh competitive pressure on UCB (ENXTBR:UCB) in a treatment area where it already markets RYSTIGGO and ZILBRYSQ. See our latest analysis for UCB. Against this backdrop of fresh competition in generalized myasthenia gravis, UCB’s share price has climbed to €279.5, with a 90 day share price return of 22.27% and a 1 year total shareholder return of...

Recent share performance and current snapshot SCR-Sibelco (ENXTBR:094426466) has been relatively stable in the very short term, with the share price flat over the past day and a modest 1.3% gain over the past week. Over longer periods, the picture is more mixed, with a small decline over the past month, a 3% gain over the past 3 months, and negative returns year to date and over the past year and the past 3 to 5 years. See our latest analysis for SCR-Sibelco. That mix of a 3.03% 90 day share...

Orange Belgium S.A.'s ( EBR:OBEL ) solid earnings announcement recently didn't do much to the stock price. Our analysis...

Most readers would already be aware that Cenergy Holdings' (EBR:CENER) stock increased significantly by 30% over the...

Sipef (ENXTBR:SIP) has reported fresh FY 2025 numbers, with first half revenue of US$250.4 million and EPS of US$5.54, set against trailing 12 month revenue of US$570.4 million and EPS of US$12.05 that came with 90.5% earnings growth over the past year. The company has seen revenue move from US$203.1 million and EPS of US$2.41 in 1H 2024 to US$239.3 million and EPS of US$3.91 in 2H 2024, before reaching the latest 1H 2025 levels. This progression gives investors a clearer run rate on both the...

If you are wondering whether Umicore is still attractively priced after a volatile few years, this article will walk through what the current share price might imply about value. Over the last year, the share price is up 102.8%, even though the 7 day and 30 day returns are 3.2% and 1.8% declines and the 3 year and 5 year returns are 36.6% and 56.1% declines, with the stock most recently closing at €19.05. These moves sit against a backdrop of ongoing attention on Umicore's role in materials...

Ontex Group (ENXTBR:ONTEX) has just posted its FY 2025 first half results, with revenue of €880.3 million and a basic EPS loss of €0.05, setting a cautious tone for how you might think about the latest numbers. Over the previous two halves in 2024, the company saw revenue move from €916.1 million in the first half to €944.4 million in the second half, while basic EPS shifted from €0.12 to €0.14, giving you a clear view of how the current setback compares to more recent profitability. With...

Montea Comm. VA (ENXTBR:MONT) has put fresh numbers on the table for FY 2025, with Q4 revenue of €56.5 million and basic EPS of €2.09, alongside trailing twelve month revenue of €167.1 million and EPS of €7.09. The company has seen quarterly revenue move from €47.5 million in Q4 2024 to €56.5 million in Q4 2025, while basic EPS shifted from €2.17 to €2.09 over the same period. This sets up a results season in which investors are weighing income appeal and reported earnings power against how...

Nextensa (ENXTBR:NEXTA) has put fresh numbers on the table for FY 2025, with first half revenue of €50.7m and basic EPS of €1.96, setting a clear marker for how the year is tracking so far. The company has seen revenue move from €65.1m in the first half of 2024 to €59.9m in the second half and then to €50.7m in the first half of 2025, while EPS shifted from €1.39 to an EPS loss of €2.48 and then back to EPS of €1.96. This gives investors a clear view of how the income line has been...

Anheuser-Busch InBev (ENXTBR:ABI) has wrapped up FY 2025 with fourth quarter revenue of about US$15.6b and basic EPS of US$0.99, rounding out a year where trailing 12 month revenue reached roughly US$59.3b and EPS came in at US$3.45. Over the past few quarters, revenue has moved from US$14.8b in Q4 2024 to US$15.0b in Q2 2025 and US$15.1b in Q3 2025, while quarterly EPS has ranged between US$0.53 and US$1.08, setting up a picture of higher trailing profitability alongside a net profit margin...

Barco (ENXTBR:BAR) has wrapped up FY 2025 with second half revenue of €509.5 million and basic EPS of €0.58, while the trailing twelve months show revenue of €963.8 million and basic EPS of €0.85, setting a clear benchmark for how the business is currently performing. The company has seen revenue move from €946.6 million to €963.8 million on a trailing basis, with basic EPS shifting from €0.71 to €0.85, giving investors a cleaner read on how profit per share is tracking alongside top line...

Fagron (ENXTBR:FAGR) reports strong full-year 2025 results. The company announces 12 acquisitions across all regions and segments. Management highlights active M&A integration alongside ongoing operations. Fagron, a global player in pharmaceutical compounding, is drawing attention with its 2025 performance and extensive deal activity. For investors following healthcare suppliers, this combination of solid reported results and a busy acquisition calendar helps frame how the company is...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...